| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 03/31/2004 | EP1402270A1 Identification of modulators of neurotransmitter activity of xanthurenic acid |
| 03/31/2004 | EP1402266A2 Determination of risk and treatment of complications of prematurity |
| 03/31/2004 | EP1402067A2 HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE |
| 03/31/2004 | EP1402066A2 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 03/31/2004 | EP1402058A2 Dgks as modifiers of the p53 pathway and methods of use |
| 03/31/2004 | EP1402054A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 03/31/2004 | EP1402053A2 CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 03/31/2004 | EP1402034A2 Identification of ses-1 and the uses of the same |
| 03/31/2004 | EP1402032A1 Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis |
| 03/31/2004 | EP1402018A1 Unigene unidirectional antisense library |
| 03/31/2004 | EP1402017A1 Random gene unidirectional antisense library |
| 03/31/2004 | EP1402009A1 Novel mixed lineage kinase (7) (mlk7) polypeptide, polynucleotides encoding the same, and methods of use thereof |
| 03/31/2004 | EP1402008A2 Method for purifying an enzyme, a purified enzyme produced thereby, and use of this enzyme |
| 03/31/2004 | EP1401870A2 Antibodies against tumor necrosis factor delta (april) |
| 03/31/2004 | EP1401861A2 Cads as modifiers of the p53 pathway and methods of use |
| 03/31/2004 | EP1401856A2 Steroid compounds, use of these compounds for the preparation of meiosis-regulating medicaments and method for the preparation of these compounds |
| 03/31/2004 | EP1401853A1 Modulators of pharmacological agents |
| 03/31/2004 | EP1401840A1 Novel 4-amino-5,6-substituted thiopheno 2,3-d]pyrimidines |
| 03/31/2004 | EP1401839A1 Antidepressant (sssri) azaheterocyclymethyl derivatives of 7,8-dihydro-3h-t,9-dioxa-1,3-diazacyclopenta a]naphthalene |
| 03/31/2004 | EP1401838A2 Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine |
| 03/31/2004 | EP1401837A1 Purine derivatives as a2b adenosine receptor antagonists |
| 03/31/2004 | EP1401835A1 Carboline derivatives as pde-5 inhibitors |
| 03/31/2004 | EP1401833A2 Chemical derivatives and the use thereof as an anti-elomerase agent |
| 03/31/2004 | EP1401831A1 Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
| 03/31/2004 | EP1401829A1 Novel heterocyclic antibacterial compounds |
| 03/31/2004 | EP1401828A1 N-formyl hydroxylamine compounds as inhibitors of pdf |
| 03/31/2004 | EP1401824A2 Aromatic hydroxamic acid derivatives useful as hdac inhibitors |
| 03/31/2004 | EP1401822A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 03/31/2004 | EP1401821A1 Novel phenylalkyl diamine and amide analogs |
| 03/31/2004 | EP1401820A1 5-ht receptor ligands and uses thereof |
| 03/31/2004 | EP1401819A1 5-ht receptor ligands and uses thereof |
| 03/31/2004 | EP1401816A1 Process for the production of the piperidine derivative fexofenadine |
| 03/31/2004 | EP1401813A1 New indole derivatives with 5-ht6 receptor affinity |
| 03/31/2004 | EP1401812A1 4-piperazinylindole derivatives with 5-ht6 receptor affinity |
| 03/31/2004 | EP1401810A1 Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use |
| 03/31/2004 | EP1401809A1 Tryptase inhibitors |
| 03/31/2004 | EP1401485A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 4-(2- 4-methane sulfonyl oxyphenyl ethoxy)phenyl] propanoic acid or 3- 4- 2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl -(s)-2-ethoxy propanoic acid and insulin |
| 03/31/2004 | EP1401481A1 Mucosal repair by tff dimer peptides |
| 03/31/2004 | EP1401480A2 Use of endostatin in the treatment of ocular neovascularization |
| 03/31/2004 | EP1401476A2 Igf antagonist peptides |
| 03/31/2004 | EP1401475A2 Prmts as modifiers of the p53 pathway and methods of use |
| 03/31/2004 | EP1401473A2 Transporters comprising spaced arginine moieties |
| 03/31/2004 | EP1401470A2 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
| 03/31/2004 | EP1401469A2 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways |
| 03/31/2004 | EP1401468A2 Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases |
| 03/31/2004 | EP1401463A1 Compositions comprising thylakoids useful in the modulation of the inflammation process |
| 03/31/2004 | EP1401461A2 Selective cox-2 inhibition from edible plant extracts |
| 03/31/2004 | EP1401460A2 Selective cox-2 inhibition from plant extracts |
| 03/31/2004 | EP1401458A2 Composition consisting of phy906 and chemotherapeutic agents |
| 03/31/2004 | EP1401453A2 Protease inhibitors |
| 03/31/2004 | EP1401451A2 Quinazoline derivatives which promote the release of parathyroid hormone |
| 03/31/2004 | EP1401449A1 Tetracyclic compounds as pde5-inhibitors |
| 03/31/2004 | EP1401444A1 Antihistamines for the treatment of nasal congestion and nasal obstruction |
| 03/31/2004 | EP1401441A2 Allosteric adenosine receptor modulators |
| 03/31/2004 | EP1401439A1 Use of bicyclo compounds for treating alzheimer's disease |
| 03/31/2004 | EP1401438A1 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors |
| 03/31/2004 | EP1401434A1 Modulators of peroxisome proliferator activated receptors (ppar) |
| 03/31/2004 | EP1401433A2 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| 03/31/2004 | EP1401431A2 Human growth hormone antagonists |
| 03/31/2004 | EP1401429A2 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
| 03/31/2004 | EP1401427A2 Non-peptide gnrh agents, pharmaceutical compositions and methods for their uses, and processes for preparing them |
| 03/31/2004 | EP1401422A2 Halogenated composition, method for preparing same and uses thereof |
| 03/31/2004 | EP1401419A1 Benzenesulfonyl(thio)ureas for the treatment of septic shock and sirs |
| 03/31/2004 | EP1401416A2 Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) |
| 03/31/2004 | EP1401415A2 Use of tyrosine kinase inhibitors for treating inflammatory diseases |
| 03/31/2004 | EP1401413A2 Use of tyrosine kinase inhibitions for treating allergic diseases |
| 03/31/2004 | EP1401412A2 Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
| 03/31/2004 | EP1401411A2 Use of tyrosine kinase inhibitors for treating bone loss |
| 03/31/2004 | EP1401410A2 Immunomodulation and effect on cell processes relating to serotonin family receptors |
| 03/31/2004 | EP1401402A2 Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin |
| 03/31/2004 | EP1401399A2 Pharmaceutical compositions containing polymer and drug assemblies |
| 03/31/2004 | EP1401393A2 No-synthase inhibitor and use thereof |
| 03/31/2004 | EP1401392A1 Ascorbyl 2-hexadecanoate as a no-synthase inhibitor |
| 03/31/2004 | EP1401390A1 Use of at least one 10-hydroxy-2-decenoic acid derivative in compositions for treating the cutaneous signs of ageing |
| 03/31/2004 | EP1401389A2 Use of carnitine and/or one or more acyl-carnitines for producing cosmetic or dermatological preparations, which increase ceramide biosynthesis |
| 03/31/2004 | EP1401383A2 Use of at least an oil extracted from the seeds of the gourd family for preparing a composition for inhibiting 5-alpha-reductase activity |
| 03/31/2004 | EP1401290A2 Composition for regulating animal growth, method of manufacture and use thereof |
| 03/31/2004 | EP1401281A2 Toll/interleukin-1 receptor adaptor protein (tirap) |
| 03/31/2004 | EP1401275A1 Antiviral composition and treatment method |
| 03/31/2004 | EP1370258A4 Peptide deformylase inhibitors |
| 03/31/2004 | EP1363623A4 Peptide deformylase inhibitors |
| 03/31/2004 | EP1294742B1 Urokinase inhibitors |
| 03/31/2004 | EP1282620B1 Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists |
| 03/31/2004 | EP1250156A4 Method for nucleic acid transfection of cells |
| 03/31/2004 | EP1232174A4 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 03/31/2004 | EP1232144B1 Novel il-8 receptor antagonists |
| 03/31/2004 | EP1210102A4 Tgf-alpha polypeptides, functional fragments and methods of use therefor |
| 03/31/2004 | EP1181294B1 Novel derivatives and analogues of galanthamin |
| 03/31/2004 | EP1177186B1 Ureas and their use as cell adhesion modulators |
| 03/31/2004 | EP1109526B1 Improved stability for injection solutions |
| 03/31/2004 | EP1095040B1 New benzoxazoles with pde-inhibiting activity |
| 03/31/2004 | EP1073438B1 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDINE)-5H-BENZO (5,6) CYCLOHEPTA (1,2-b) PYRIDINE ORAL COMPOSITIONS |
| 03/31/2004 | EP1053020B1 Absorbable microparticles |
| 03/31/2004 | EP1025098B1 Benzothiophenes |
| 03/31/2004 | EP0996431B1 Synergistic compositions of lycopene and vitamin e for the prevention of ldl oxidation |
| 03/31/2004 | EP0994705B1 Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides |
| 03/31/2004 | EP0977578B1 Compositions to enhance the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants |
| 03/31/2004 | EP0939625B1 2-cyclopenten-1-one as an inducer of hsp70 |
| 03/31/2004 | EP0935652B1 Keratinocyte growth factor-2 products |
| 03/31/2004 | EP0901470B1 Indole derivatives useful as endothelin receptor antagonists |